Clinical cure · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (pneumonia-associated) · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · children under 5 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to cessation of bleeding · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BMD Z score (lumbar spine) · adults and children with cystic fibrosis
1 finding from 1 review
QoL · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PIVKA II levels: change in PIVKA II (ng/mL) · adults and children with cystic fibrosis
1 finding from 1 review
Uncarboxylated osteocalcin: change in carboxylation of osteocalcin (% Glu‐OC) · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
VITAMIN E showed no clear difference in tardive dyskinesia: 1. Not improved to a clinically important extent compared with PLACEBO (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
VITAMIN E may leads to lower tardive dyskinesia: 3. Deterioration of symptoms compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effect: any · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether VITAMIN E changes adverse effect: any compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether VITAMIN E changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Cognitive subdomain: episodic memory measured at the end of · MCI
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Executive functioning · MCI
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Quality of life ‐ not measured · MCI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · MCI
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Incidence of dementia due to Alzheimer's disease · MCI
1 finding from 1 review